5 Top Weekly NASDAQ Biotech Stocks: Immune Design Soars

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) had a bit of a rollercoaster week over the course of the trading period, starting the week off at 3,497.61 points and dipping sharply on Thursday (February 21) to 3,422.73 points.

By Friday’s trading session, the index had made a slight recovery to 3,473.53 points as of 1:49 p.m. EST.

Last week, the Investing News Network (INN) had the opportunity to speak with David Moss, CFO of INmune Bio (NASDAQ:INMB), about the US$1 million grant it received from the Alzheimer’s Association to develop its latest drug candidate, Xpro1595, to treat Alzheimer’s disease.

While the company is primarily focused on on developing therapies geared towards the innate immune system in cancer, Moss told INN the company is excited pursuing a clinical trial for Xpro1595 with support from the Alzheimer’s Association.

“We weren’t going to pursue it unless we had the backing and support of a third party group,” Moss said. [W]hen the Alzheimer’s Association stepped forward, we were just absolutely ecstatic to move forward with the clinical trial,” Moss said.

On that note, a number of NASDAQ biotech stocks were in the green last week, including:

• Immune Design (NASDAQ:IMDZ)
• Zosano Pharma (NASDAQ:ZSAN)
• Achieve Life Sciences (NASDAQ:ACHV)
• Insys Therapeutics (NASDAQ:INSY)
• MediciNova (NASDAQ:MNOV)

Here’s a closer look at those companies and what may have moved their share prices last week.

Immune Design

First in our five top weekly NASDAQ biotech stocks list is Immune Design, which is a late-stage immunotherapy company working to develop in vivo approaches to help the body’s immune system fight diseases, including cancer and other chronic diseases.

Immune Design’s lead candidate, G100, is a potent intratumoral TLR4 agonist that has demonstrated clinical benefits in a variety of tumors.

On Thursday, it was revealed that Merck (NYSE:MRK) will be acquiring Immune Design for US$300 million. According to the announcement, the deal is expected to close sometime in early Q2 2019.

Shares of Immune Design rose sharply throughout the week, increasing by a staggering 297.95 percent to reach US$5.82.

Zosano Pharma

Second on our weekly NASDAQ biotech stocks list is Zosano Pharma, a clinical-stage biopharmaceutical company which has a focus on its lead clinical asset, Qtrypta, which is designed to treat migraines and migraine symptoms.

The drug has completed the ZOTRIP trial, and has just completed the long-term safety study, the company announced on Thursday. According to the press release, over a one-year period, the clinical program treated over 5,800 migraine attacks.

Unsurprisingly, shares of Zosano Pharma were up 106.3 percent last week to close on Friday at US$4.54.

Achieve Life Sciences

Middle of the pack on our five top weekly NASDAQ biotech stocks list is Achieve Life Sciences, which is a specialty pharmaceutical company. Achieve Life Sciences if focused on advancing cytisincline to help people quit smoking.

Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotine receptor.

Achieve Life Sciences announced on Friday final data from its Phase I/II multi-dose, pharmacokinetic and pharmacodynamics clinical study of cytisinicline in smokers. According to the release, all patients had a significant reduction in smoking cigarettes within two days of starting the cytisinicline treatment.

Shares of Achieve Life Sciences were up 94.11 percent last week to US$3.30.

Insys Therapeutics

Next is Insys Therapeutics, which is specialty pharmaceutical company developing and commercializing innovative drugs and novel drug delivery systems of therapeutic molecules to improve quality of life.

The company’s approved product, SUBSYS, is the first and only breakthrough pain medication for patients with cancer as a sublingual spray.

However, the company didn’t have any news last week that could relate to its share price hike, which increased 25.97 percent last week to US$6.16.

MediciNova

Closing out our list is MediciNova, which is a biopharmaceutical company targeting neurology, respiratory and liver diseases with unmet medical needs.

The company’s current focus is on on MN-166 (ibudilast) for neurological disorders ranging from progressive multiple sclerosis, amyotrophic lateral sclerosis, substance dependence, and glioblastoma to name a few.

That said, the company did not have any news last week that could relate to its share price hike. Still, its share price increase is worth noting. Over the week, MediciNova’s share price rose 22 percent to US$8.64.

NASDAQ Biotech Stocks articles is retrieved each Friday at 1:00 p.m. EST using TradingView’s Stock Screener. Only companies with a market capitalization greater than $50 million and lower than $500 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.

Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.

This article is updated each week. Please scroll to the top for the most recent information.

5 Top Weekly NASDAQ Biotech Stocks: Index in the Green Again

By Jocelyn Aspa, February 17, 2019

Last week, the NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) was back in the green, rising from 3,405.25 points on Monday’s (February 11) open to 3,497.09 points as of 1:20 p.m. EST on Friday (February 15).

On Wednesday (February 13), it was revealed a new listing would be joining the exchange — TCR² Therapeutics (NASDAQ:TCRR) — which officially began trading its common stock on Thursday. TCR is a clinical-stage immunotherapy company developing novel T cell receptor therapies for cancer patients.

Meanwhile a number of other NASDAQ biotech stocks were on the rise last week, including:

• ConforMIS (NASDAQ:CFMS)
• CAS Medical Systems (NASDAQ:CASM)
• ADMA Biologics (NASDAQ:ADMA)
• Outlook Therapeutics (NASDAQ:OTLK)
• Citius Pharmaceuticals (NASDAQ:CTXR)

Here’s a closer look at those companies and what may have moved their share prices over the week.

ConforMIS

First on our five top weekly NASDAQ biotech stocks list is ConforMIS. ConforMIS designs and develops knee implants using 3D printing to make knee implants for all stages of osteoarthritis of the knee.

The company has three core products, including: the iTotal, which are custom-made cruciate-retaining and posterior stabilizing knee replacements, the iUni and iDuo, which are patient-specific knee replacement options, and the iJig instrumentation, which is a 3D printed surgical instrumentation specific to each patient.

Last week, shares of ConforMIS increased 63.89 percent to reach US$1.15 as of 2:07 p.m. EST on Friday. However, the company didn’t have any news last week that could be attributed to its share price hike.

CAS Medical Systems

CAS Medical Systems is a medical technology company that is developing tissue oximetry devices, including the Fore-Sight Ceberal Oximetry device, which is geared towards detecting hypoxia. The device allows for non-invasive measurements of tissue oxygenation in the brain.

On Tuesday (February 12), it was announced that the company will be acquired by Edwards Lifesciences (NYSE:EW), which means CAS Medical Systems won’t be on this list for much longer. According to the release, the deal is expected to close sometime in the second quarter of this year.

Shares of CAS Medical Systems were up 52.20 percent to settle at US$2.42 as of 2:20 p.m. EST on Friday.

ADMA Biologics

Middle of the pack on our five top weekly NASDAQ biotech stocks list is ADMA Biologics, which is a company focusing on creating products for patients immunodeficient patients with risks of getting infections.

ADMA is currently developing its lead product candidate, RI-002 to treat primary immunodeficiency disease (PIDD), and has completed a Phase III clinical study. PIDD are genetic disorders that causes deficient or absent immune system due to a lack of necessary antibodies or a failure of these antibodies to function properly.

The company announced on Tuesday that it had entered into a staggering US$72.5 million senior secured term loan facility with Perceptive Advisors. The first $45 million will go towards ADMA’s former senior secured credit facility of $30 million in full plus associated costs and fees. The rest of the $27.5 million is predicated on the US Food and Drug Administration (FDA)’s approval of the company’s BIVIGAM® Prior Approval Supplement or the RI-002 Biologics License Application.

Shares of ADMA were up 47.29 percent last week to US$4.25 as of 2:38 p.m. EST on Friday.

Outlook Therapeutics

Outlook Therapeutics is a late clinical-stage biopharmaceutical company and is currently focused on developing its ONS-5010 product geared towards ophthalmic indications, in particular for the treatment of wet AMD and other retina diseases.

On Thursday, Outlook Therapeutics released its fiscal first quarter results for the period ended December 31, 2018. In the results, the company highlighted it had completed 75 percent enrollment of its ONS-5010-001, a Phase 3 clinical trial in wet AMD.

Shares of Outlook Therapeutics were unsurprisingly on the rise last week, increasing by 41.29 percent to reach US$1.30 as of 2:44 p.m. EST on Friday.

Citius Pharmaceuticals

Rounding out our five top weekly NASDAQ tech stocks is Citius Pharmaceuticals, which is a specialty pharmaceutical company that is developing critical care products.

The company’s key product includes the Mino-Lok™, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). The product is currently heading towards a Phase 3 study after completing a Phase 2a study for hydrocortisone-lidocaine formulation for Grade I and II hemorrhoids.

That said, Citius Pharmaceuticals did not have any news last week, although its share price increase is still worth noting. Over the five-day trading period, the company’s stock bumped up 33.72 percent to US$1.19 as of 2:55 p.m. EST on Friday.

 NASDAQ Biotech Stocks articles is retrieved each Friday at 1:00 p.m. EST using TradingView’s Stock Screener. Only companies with a market capitalization greater than $50 million and lower than $500 million prior to the week’s gains are included. Companies within the biotechnology and pharmaceutical sectors are considered.

Securities Disclosure: I, Jocelyn Aspa, hold no direct investment interest in any company mentioned in this article.